Literature DB >> 9668544

Survival and disease complications in thalassemia major.

C Borgna-Pignatti1, S Rugolotto, P De Stefano, A Piga, F Di Gregorio, M R Gamberini, V Sabato, C Melevendi, M D Cappellini, G Verlato.   

Abstract

We studied survival and disease complications in 1,146 patients with thalassemia major, born from January 1, 1960 to December 31, 1987. At last follow-up, in March 1997, probability of survival to age 20 years was 89% and to age 25 years was 82% for patients born in the years 1970-1974. Patients who died had a serum ferritin level, measured the year before death, significantly higher than those who survived. Diabetes was present in 5.4% of the patients; heart failure in 6.4%; arrhythmias in 5.0%, thrombosis in 1.1%, hypothyroidism in 11.6%, HIV infection in 1.8%. Hypogonadism was diagnosed in 55% of 578 patients who had reached pubertal age: 83.5% of hypogonadic females and 78.6% of males were receiving substitutive hormonal therapy. In conclusion, the survival of patients with thalassemia major is good and improving, but the prevalence of severe complications is still high.

Entities:  

Mesh:

Year:  1998        PMID: 9668544     DOI: 10.1111/j.1749-6632.1998.tb10479.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  53 in total

1.  Occurrence of overwhelming gram-negative infections in splenectomised patients with thalassaemia major.

Authors:  Mardawig Alebouyeh; Farideh Moussavi
Journal:  Eur J Pediatr       Date:  2003-06-17       Impact factor: 3.183

Review 2.  Diabetes and hemochromatosis.

Authors:  T Creighton Mitchell; Donald A McClain
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

3.  Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.

Authors:  Patrick B Walter; Ellen B Fung; David W Killilea; Qing Jiang; Mark Hudes; Jacqueline Madden; John Porter; Patricia Evans; Elliott Vichinsky; Paul Harmatz
Journal:  Br J Haematol       Date:  2006-10       Impact factor: 6.998

4.  Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.

Authors:  Maya Otto-Duessel; Michelle Aguilar; Hanspeter Nick; Rex Moats; John C Wood
Journal:  Exp Hematol       Date:  2007-07       Impact factor: 3.084

5.  Cardiovascular magnetic resonance and thalassaemia.

Authors:  J P Carpenter; D J Pennell
Journal:  Int J Cardiovasc Imaging       Date:  2008-09-02       Impact factor: 2.357

6.  Early electrocardiographic evaluation of atrial fibrillation risk in beta-thalassemia major patients.

Authors:  Vincenzo Russo; Anna Rago; Bruno Pannone; Federica Di Meo; Andrea Antonio Papa; Maria Carolina Mayer; Anna Spasiano; Maria Giovanna Russo; Paolo Golino; Raffaele Calabrò; Gerardo Nigro
Journal:  Int J Hematol       Date:  2011-03-10       Impact factor: 2.490

Review 7.  Iron and diabetes risk.

Authors:  Judith A Simcox; Donald A McClain
Journal:  Cell Metab       Date:  2013-03-05       Impact factor: 27.287

8.  In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: a consequence of splenectomy.

Authors:  Vichai Atichartakarn; Pantep Angchaisuksiri; Katcharin Aryurachai; Suporn Chuncharunee; Ammarin Thakkinstian
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

9.  History and current impact of cardiac magnetic resonance imaging on the management of iron overload.

Authors:  John C Wood
Journal:  Circulation       Date:  2009-11-02       Impact factor: 29.690

10.  Cost analysis of iron-related complications in a single institute.

Authors:  Ki Hwan Kim; Jin Won Kim; Ji Young Rhee; Min Kyung Kim; Byung Su Kim; Inho Kim; Soo Mee Bang; Sung Soo Yoon; Jong Seok Lee; Kyou Sup Han; Seonyang Park; Byoung Kook Kim
Journal:  Korean J Intern Med       Date:  2009-03       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.